PCSK9 and cardiovascular disorder: Use of the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor evolocumab reduces low-density lipoprotein (LDL) cholesterol by ~60% and lowers the rate of cardiovascular events among patients with established cardiovascular disease [1].